![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The net proceeds will be used for the development of chimeric antigen receptor T cell therapy program, at an advanced stage for Cellogen Therapeutics, where the T cells of the patients are genetically engineered to identify and kill the cancer cells.
Lead Product(s): CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Natco Pharma
Deal Size: $2.0 million Upfront Cash: Undisclosed
Deal Type: Financing January 18, 2024